Analysis of U.S. Patent 4,366,310: Cyclodextrin Complexation of Prostaglandins
U.S. Patent 4,366,310, issued on January 3, 1983, to The Upjohn Company, details a method for forming cyclodextrin complexes of prostaglandins. The patent claims a process for enhancing the stability and bioavailability of prostaglandin compounds through encapsulation with cyclodextrins. This technology is relevant to pharmaceutical formulations of prostaglandins, which are a class of potent lipid compounds with diverse physiological functions.
What is the core invention claimed in U.S. Patent 4,366,310?
The patent claims a process for preparing stable, water-soluble complexes of prostaglandins. The invention centers on the inclusion of prostaglandin molecules within the cavity of cyclodextrins, a group of cyclic oligosaccharides. This complexation method aims to protect the labile prostaglandin structure from degradation and improve its solubility in aqueous media.
Key aspects of the claimed process:
- Prostaglandin Selection: The process is applicable to a wide range of prostaglandins, including naturally occurring ones and their synthetic analogs. This encompasses compounds from the A, B, E, F, and D series.
- Cyclodextrin Selection: The patent specifies the use of alpha-, beta-, or gamma-cyclodextrins, or their derivatives. Beta-cyclodextrin is frequently cited in examples due to its favorable cavity size and commercial availability.
- Complex Formation: The complex is formed by mixing a prostaglandin with a cyclodextrin in an aqueous medium. The prostaglandin molecule, typically hydrophobic, is partially or fully encapsulated within the hydrophobic interior of the cyclodextrin, while the exterior of the cyclodextrin remains hydrophilic.
- Stabilization Mechanism: The cyclodextrin cavity shields the reactive functional groups of the prostaglandin from environmental factors such as oxidation, hydrolysis, and light, thereby increasing its shelf life.
- Solubility Enhancement: The hydrophilic exterior of the cyclodextrin complex renders the usually poorly water-soluble prostaglandin more soluble in aqueous solutions, which is crucial for pharmaceutical administration.
What are the specific claims of U.S. Patent 4,366,310?
U.S. Patent 4,366,310 contains several claims defining the scope of the invention. These claims are critical for understanding what is protected and any potential infringement.
Claim 1 is the independent claim defining the core process:
A process for preparing a stable, water-soluble complex of a prostaglandin which comprises intimately contacting from about 0.1 to about 50 parts by weight of a prostaglandin with from about 1 to about 100 parts by weight of a cyclodextrin in an aqueous medium.
Dependent claims further define specific embodiments and limitations:
- Claim 2: Specifies the use of prostaglandins of the A, B, E, F, or D series.
- Claim 3: Limits the prostaglandin to those of the E or F series.
- Claim 4: Specifies the cyclodextrin as alpha-, beta-, or gamma-cyclodextrin.
- Claim 5: Further limits the cyclodextrin to beta-cyclodextrin.
- Claim 6: Defines the aqueous medium as water.
- Claim 7: Mentions a "complex" consisting of intimately admixed prostaglandin and cyclodextrin.
- Claim 8: Defines a "water-soluble complex" containing a prostaglandin and a cyclodextrin.
These claims establish a method for forming complexes and the resulting complex itself. The patent does not claim the prostaglandins themselves, but rather the method of complexing them with cyclodextrins and the resultant stable, water-soluble complex.
How does the patent address the stability and bioavailability of prostaglandins?
The patent directly addresses the inherent instability and poor water solubility of prostaglandins, which are major challenges for their pharmaceutical development and delivery.
Stability:
Prostaglandins are sensitive to heat, light, oxygen, and pH fluctuations. Their therapeutic efficacy can be significantly reduced by degradation. The cyclodextrin encapsulation, as described in the patent, provides a physical barrier around the prostaglandin molecule. This barrier limits the access of degrading agents to the prostaglandin, thereby extending its shelf life and maintaining its potency. The hydrophobic cavity of the cyclodextrin offers a microenvironment that protects the sensitive functional groups of the prostaglandin.
Bioavailability:
Many prostaglandins are administered parenterally due to poor oral absorption and rapid metabolism. Their low water solubility further complicates formulation for various routes of administration, including intravenous and topical. By forming a water-soluble complex with cyclodextrin, the patent aims to:
- Increase solubility: This allows for the preparation of higher concentration aqueous solutions, facilitating easier administration and potentially enabling new delivery routes.
- Improve absorption: Enhanced solubility can lead to better absorption across biological membranes, increasing the amount of active drug reaching the systemic circulation or target site.
- Control release: While not explicitly detailed as a primary claim, cyclodextrin complexation can sometimes influence the release kinetics of the encapsulated drug, potentially leading to sustained or controlled release profiles.
The patent's examples demonstrate this improvement by showing increased solubility of prostaglandins like dinoprost (PGF2α) and dinoprostone (PGE2) in the presence of cyclodextrins compared to their solubility in plain water.
What is the patent landscape surrounding U.S. Patent 4,366,310?
The issuance of U.S. Patent 4,366,310 in 1983 places it within a historical context of prostaglandin research and pharmaceutical formulation. At the time of its filing, cyclodextrin technology was emerging as a promising tool for drug delivery.
Prior Art:
The patent acknowledges existing knowledge of prostaglandins and their therapeutic uses, as well as the properties of cyclodextrins. The novelty of the invention lies in the specific application of cyclodextrin complexation to enhance the stability and solubility of prostaglandins, addressing their unique formulation challenges. Prior art would likely have focused on other methods of stabilizing prostaglandins or improving their solubility, such as liposomal encapsulation or the use of co-solvents.
Subsequent Developments and Related Patents:
The technology described in U.S. Patent 4,366,310 has been foundational for subsequent research and patenting in the area of cyclodextrin-based drug delivery. Many later patents likely build upon this concept, focusing on:
- Specific prostaglandin derivatives: New synthetic prostaglandins with improved therapeutic profiles may also be complexed with cyclodextrins.
- Modified cyclodextrins: Derivatives of cyclodextrins (e.g., hydroxypropyl-beta-cyclodextrin, sulfobutyl ether beta-cyclodextrin) offer enhanced solubility and reduced toxicity, and their use with prostaglandins would be a logical progression.
- Specific formulations and delivery systems: Patents may claim specific pharmaceutical compositions incorporating cyclodextrin-prostaglandin complexes for particular routes of administration (e.g., ophthalmic solutions, nasal sprays, injectables).
- Manufacturing processes: Improved or scaled-up methods for producing these complexes might be patented.
Key Companies and Research Areas:
The Upjohn Company, the assignee of this patent, was a significant pharmaceutical entity in the prostaglandin field. Companies involved in prostaglandin therapeutics and drug delivery technologies would be interested in this patent and its progeny. This includes companies developing treatments for:
- Glaucoma (e.g., latanoprost, travoprost)
- Reproductive health (e.g., labor induction, post-partum hemorrhage)
- Gastrointestinal disorders
- Cardiovascular conditions
The patent's expiration date (January 3, 2000) means its core claims are no longer in force. However, the principles it established are still relevant, and subsequent patents may cover newer formulations or related technologies that indirectly relate to its early contributions.
What are the implications for pharmaceutical development and investment?
U.S. Patent 4,366,310 represents an early but significant contribution to the pharmaceutical formulation of prostaglandins. For professionals involved in R&D or investment, understanding this patent's scope and historical context is important.
For R&D:
- Foundation for current formulations: The principles of cyclodextrin complexation for prostaglandin stabilization and solubility are likely incorporated into many existing and developmental prostaglandin-based drugs.
- Inspiration for novel delivery: While the core patent is expired, the concept of using supramolecular structures like cyclodextrins for drug delivery remains a vibrant area of research. New cyclodextrin derivatives or novel complexation techniques could offer further advantages.
- Addressing formulation challenges: For new prostaglandin analogs or other poorly soluble drugs with similar structural vulnerabilities, cyclodextrin complexation remains a viable strategy.
For Investment:
- Freedom to Operate (FTO): Since the patent is expired, it does not pose a direct FTO barrier for developing generic versions of prostaglandin formulations that only rely on the methods claimed in this patent. However, any new formulation or delivery system would need to be assessed against currently active patents covering specific drug substances, dosages, delivery devices, or advanced formulation techniques.
- Understanding historical IP strategy: The patent illustrates a strategy to protect a formulation technology rather than just the active pharmaceutical ingredient (API). This approach is common in the pharmaceutical industry and influences how companies build their IP portfolios.
- Evaluating emerging technologies: Investors looking at companies developing prostaglandin-based drugs should assess their IP strategy concerning formulation. Are they leveraging established technologies like cyclodextrin complexation, or are they developing novel, potentially patentable delivery systems?
The patent’s expiration signifies that the basic method of complexing prostaglandins with cyclodextrins is in the public domain. However, the complexity of pharmaceutical IP means that novel applications, specific combinations, or improved processes related to this fundamental invention may still be protected by more recent patents.
Key Takeaways
U.S. Patent 4,366,310 describes a method for enhancing prostaglandin stability and water solubility through cyclodextrin complexation. The patent claims the process of forming these complexes and the resulting stable, water-soluble complexes. Prostaglandins are protected from degradation within the cyclodextrin cavity, and their solubility is increased by the hydrophilic exterior of the cyclodextrin. The patent expired in 2000, making the core technology publicly available. However, subsequent patents may cover advanced cyclodextrin derivatives, specific prostaglandin analogs, or novel formulations built upon this foundational work.
FAQs
-
What is the expiry date of U.S. Patent 4,366,310?
U.S. Patent 4,366,310 expired on January 3, 2000.
-
Does this patent cover the prostaglandins themselves?
No, the patent does not claim the prostaglandin molecules. It claims the method of complexing them with cyclodextrins and the resultant complexes.
-
Can current companies use cyclodextrin complexation for prostaglandin formulations?
Yes, the core claims of this patent are expired, meaning the basic method is in the public domain. However, any new formulation must be assessed against other active patents covering specific drugs, formulations, or delivery systems.
-
What are some examples of prostaglandins that can be complexed using this method?
The patent covers prostaglandins from the A, B, E, F, and D series, including naturally occurring ones and synthetic analogs like dinoprost and dinoprostone.
-
What are the main benefits of cyclodextrin complexation for prostaglandins, according to the patent?
The main benefits are enhanced stability by protecting the prostaglandin from degradation and improved water solubility, facilitating pharmaceutical formulation and delivery.
Citations
[1] F. R. Van Vlack, U.S. Patent 4,366,310 (January 3, 1983).
